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eIF6 coordinates insulin sensitivity and lipid
metabolism by coupling translation to transcription
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Insulin regulates glycaemia, lipogenesis and increases mRNA translation. Cells with reduced
eukaryotic initiation factor 6 (eIF6) do not increase translation in response to insulin. The role
of insulin-regulated translation is unknown. Here we show that reduction of insulin-regulated
translation in mice heterozygous for eIF6 results in normal glycaemia, but less blood
cholesterol and triglycerides. eIF6 controls fatty acid synthesis and glycolysis in a cell
autonomous fashion. eIF6 acts by exerting translational control of adipogenic transcription
factors like C/EBPb, C/EBPd and ATF4 that have G/C rich or uORF sequences in their 50 UTR.
The outcome of the translational activation by eIF6 is a reshaping of gene expression with
increased levels of lipogenic and glycolytic enzymes. Finally, eIF6 levels modulate histone
acetylation and amounts of rate-limiting fatty acid synthase (Fasn) mRNA. Since obesity, type
2 diabetes, and cancer require a Fasn-driven lipogenic state, we propose that eIF6 could be a
therapeutic target for these diseases.
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I
nsulin controls glycaemia. Insulin resistance, the lack of
responsiveness to insulin, is at the basis of the pathogenesis of
many metabolic disorders, widespread in the world population
and constantly growing1. Nonalcoholic fatty liver disease is the
most common liver disorder in the Western world2 and is
universally associated with hepatic insulin resistance, which
increases the risk of impaired control of fasting glycaemia and of
type 2 diabetes3. The understanding of the molecular mechanism
of insulin action provides a tool to optimize strategies to
overcome insulin resistance.
Insulin induces a multifocal response that includes glucose
uptake, signalling to the transcriptional machinery and an
increase in translation4. It is well know how insulin transmit
signals to the translational machinery5. Brieﬂy, mTOR kinase is a
central player in translation6. Insulin stimulates mTORc1
(complex I) and mTORc2 (complex 2) activity. mTORc1
regulates the formation of the cap complex eIF4F and it
phosphorylates 4E-BPs, releasing the cap complex binding
protein eIF4E (ref. 7). Free eIF4E assembles in the eIF4F
complex, which contains mRNA, eIF4A helicase and eIF4G.
The eIF4F complex binds 43S ribosomal subunits leading to the
formation of 48S preinitiation complexes and subsequent
activation of cap-dependent translation. Therefore, the insulin-
mTORc1-eIF4F axis controls the translational efﬁciency of
speciﬁc mRNAs downstream of mTORc1 activity. In the
context of insulin, inactivation of regulators 4E-BP1 and
4E-BP2 causes insulin resistance8, and treatment with
rapamycin and its analogues (rapalogues) generates glucose
intolerance9 or even the onset of insulin resistance10. These
data leave unresolved the issue on the druggability of the
translational apparatus in metabolic syndromes. In cycling cells,
mTOR activation results in the induction of cell growth and
cell cycle progression7. Consistently, inhibition of mTORc1
dependent translation by rapalogs has an anti-neoplastic effect
in selective cancers with PI3K-mTOR activation11,12.
The RAS/MAPK pathway converges also on translation7.
Cancer patients with RAS mutations are insensitive to mTORc1
inhibition13. The insensitivity to rapamycin inhibition of cells
with mutated RAS suggests that other initiation factors act
independently from mTOR among them, eIF4E and eIF6. eIF4E
phosphorylation is regulated by the RAS-Mnk1/2 cascade and, in
the context of cancer, constitutive eIF4E activation is associated
with tumour progression14,15. eIF6 is an initiation factor acting
independently from mTOR16. eIF6 heterozygosity restrains
tumourigenesis and leads to a striking increased survival in a
mouse model of Em-Myc lymphoma17. eIF6 ampliﬁcation occurs
in luminal breast cancer18. eIF6 is an anti-association factor that
prevent formation of inactive 80S complex, by binding to 60S
(ref. 19). eIF6 phosphorylation is stimulated by phorbol esters
inducing protein kinase C (PKC) activation and in response to
insulin20. The C terminus of eIF6 has multiple phosphorylation
sites including Ser235 (ref. 21). Normal eIF6 sustains translation,
whereas a Ser235Ala mutant does not22. The protective effects of
eIF6 depletion on tumour growth and the speciﬁc action of eIF6
on insulin-stimulated translation suggest that eIF6 and 60S
availability control the translation of speciﬁc mRNAs. eIF6 has
been reported to regulate miRNA-based repression, but this role
has not been conﬁrmed by further studies23. Thus eIF6 targets
remain unknown.
Driver regulatory cis-sequences in the 50 untranslated region
(UTR) or 30 UTR of mRNAs may account for differential
translation. Growth factors stimulate the translation of
50structured or G/C containing mRNAs that encode for proteins
necessary for cell cycle progression24 and/or of terminal
oligopyrimidine tract (TOP) mRNAs encoding for ribosomal
proteins25,26 or pyrimidine-rich translational elements25. Cellular
Internal Ribosome Entry Site may sustain translation in the
absence of nutrients27. Upstream open reading frame (uORF)
sequences regulate translation in conditions of amino-acid
deprivation, dsRNA infection, unfolded protein response
(UPR)28. Loss of eIF4F integrity by eIF4G depletion has been
shown to affect polysomal association of uORF-containing
mRNAs, suggesting that uORFs might have other functions,
independent from amino-acid deprivation or UPR29.
In conclusion several questions arise: (i) what is the
physiological action of the insulin-eIF6 axis? (ii) are speciﬁc
mRNAs preferentially translated upon activation of eIF6? (iii) is
eIF6 targetable? To address these questions we combined analysis
on mouse, human and cellular models. We found that eIF6
translational activity is necessary to co-ordinate an integrated
translational response that shapes the metabolism of cells. We
show that eIF6 is an initiation factor that activates de novo
lipogenesis and affects insulin sensitivity. Our data support a
model in which eIF6-driven translation reinforces insulin-
stimulated lipid synthesis and may become a therapeutic target
in metabolic syndromes.
Results
eIF6 is required for efﬁcient lipid synthesis in vivo. eIF6
heterozygous (het) cells express 50% eIF6 compared with wild
type (wt), have normal basal translation, but impaired insulin-
stimulated translation22. eIF6 het mice are healthy, leaner22 and
resistant to Myc-induced lymphomagenesis compared with wt
ones17. We employed a cohort of wt and het mice, n¼ 40, in a
pure C57BL/6 genetic background (Supplementary Fig. 1a,b). We
analysed liver polysome peaks as an indicator of initiation of
translation, in vivo, after feeding. Polysomes from eIF6 het mice
were lower than in wt, consistent with reduced initiation of
translation, in vivo (Fig. 1a) after feeding. During fasting, eIF6
het mice displayed a polysome proﬁle similar to wt ones
(Supplementary Fig. 1c). This model therefore allows the
analysis of the physiological role of translation in vivo, after
feeding. We ﬁrst asked whether glycemic control is maintained in
conditions of eIF6 deﬁciency. To evaluate glucose tolerance, we
performed a glucose tolerance test (GTT). We found that eIF6 het
mice had normal response to glucose load (Fig. 1b). A broad
clinical chemistry analysis revealed that in refed conditions eIF6
het mice had reduced blood cholesterol levels (Fig. 1c),
triglycerides (Fig. 1d), liver triglycerydes (Fig. 1e), non-essential
fatty acids (Supplementary Fig. 1d). Glycaemia was slightly lower
in both fasted and refed conditions (Supplementary Fig. 1d).
Insulin levels were lower in fasting conditions (Supplementary
Fig. 1d). All other parameters in fasting were identical between wt
and het mice (Supplementary Fig. 1d). Markers for hepatic
function were identical between wt and het mice, suggesting
overall normal hepatic function (Supplementary Fig. 1e). In liver,
insulin stimulates glucose storage through stimulation of
glycogen synthesis. We found that eIF6 het had glycogen levels
identical to wt mice (Supplementary Fig. 1f,g). Liver ATP levels
were lower in eIF6 het mice compared to wt (Fig. 1f). In
conclusion, eIF6 mice have impaired insulin-stimulated
translation22 accompanied by reduction of blood and liver lipid
levels without impairment of glucose blood control and glycogen
synthesis.
To deﬁne whether the translational deﬁcit on insulin stimula-
tion has an impact in pathological conditions, we tested the
response of eIF6 het mice to a high-fat diet (HFD) regimen: we
found that eIF6 het mice had a reduced weight gain during HFD
compared with wt controls (Fig. 1g) but no substantial difference
in glucose tolerance (Supplementary Fig. 1h) and insulin levels at
time 0 (Supplementary Fig. 1i). Nonetheless, insulin levels were
signiﬁcantly lower in het mice compared with wt mice after
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120min from glucose injection (Fig. 1h). However, an insulin
tolerance test (ITT) showed that eIF6 het mice responded better
to insulin (Fig. 1i; Supplementary Fig. 1j). Following a HFD, eIF6
het mice showed increased liver-X-ray attenuation and decreased
triglycerides (TG) levels compared with wt mice (Fig. 1j,k)
demonstrating reduced hepatic lipid content. At autopsy, eIF6 het
livers were less enlarged (Supplementary Fig. 1k). We analysed
whether a relationship between eIF6 levels and insulin resistance,
could be found in humans. The homoeostasis model assessment
of insulin resistance (HOMA-IR) is an established measure of
whole-body insulin sensitivity, the higher the value the more
insulin resistant. We data-mined the relationship between
subcutaneous fat expression levels of eIF6 and HOMA-IR. We
found (Fig. 1l) that eIF6 expression negatively correlates with
insulin sensitivity, as an independent factor (Fig. 1l).
In conclusion, our data demonstrate that the impairment of
translation due to eIF6 depletion affects liver lipid metabolism
leading to reduced susceptibility to hepatic lipid accumulation.
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Figure 1 | eIF6 depletion impairs polysome formation in the liver after feeding, reduces lipidemia, protects from HFD and liver steatosis. All graphs,
black, wt; red, eIF6 het mice (a) Representative liver polysomal proﬁles of wt (black) and eIF6 het (red, þ / ) show reduced polysomes in het after
overnight fasting and 4 h refeeding. Experiment repeated at least ﬁve times. (b) GTT is normal in eIF6 het (red) compared with wt. N¼ 7. (c,d) Cholesterol
and triglycerides levels are reduced in blood of eIF6 het compared with wt ones (N¼ 10). (e) Liver triglyceride content is reduced in eIF6 het mice (N¼4).
(f) ATP liver content is reduced in eIF6 het. N¼ 3. (g) eIF6 het mice are protected from HFD: body weight gain is reduced in eIF6 het mice compared with
wt. N¼ 10. Top bars show absolute body weight gain. Lower graph, body weight. (h) GTT eIF6 het mice have lower insulinaemia at 2 h after glucose
injection. N¼ 10. (i) ITT (AUC ITT, area under curve) shows partial amelioration of diet-induced insulin resistance. N¼ 5 (j,k). Increased liver-X-ray
attenuation (N¼8) indicating reduced fat deposition in the liver (j) conﬁrmed by autoptic liver triglyceride content on separate animals (N¼ 5) (k).
(i) In humans, eIF6 levels inversely correlate with insulin sensitivity, as measured by HOMA-IR. In all panels, data are represented as mean±s.d. Statistical
P values were calculated by two-tailed t-test (*P value r0.05).
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eIF6 stimulates fatty acid synthesis cell autonomously. Changes
in blood cholesterol and in ATP liver levels raise the question
whether the metabolic changes driven by eIF6 are cell autono-
mous or due to indirect systemic events such as, for instance,
reduced food intake/absorption or increased basal metabolic rate.
We analysed metabolic parameters from primary hepatocytes
isolated from mice (Fig. 2a). eIF6 het hepatocytes have 50% eIF6
protein compared with wt (Supplementary Fig. 2a), and, con-
sistent with the in vivo phenotype, they fail to increase protein
synthesis after insulin stimulation (Supplementary Fig. 2b).
Glucose uptake of eIF6 het cells was identical to wt, consistent
with the normal GTT observed in vivo (Supplementary Fig. 2c).
Glucose uptake was also normal in eIF6-depleted 3T3-L1 cells
(Supplementary Fig. 2d). Notably, primary eIF6 het hepatocytes,
compared with wt ones, showed a signiﬁcant reduction of de novo
lipogenesis (Fig. 2b). Insulin stimulates glycolysis. We found that
primary het hepatocytes had a signiﬁcant reduction of glycolysis,
as measured by lactate secretion (Fig. 2c). Fatty acid oxidation
under feeding (Fig. 2d) was not signiﬁcantly changed between wt
and het. Hepatocytes from eIF6 het mice also had a reduction in
ATP concentration (Fig. 2e). These results mirror the liver con-
dition, in vivo, as described in Fig. 1. To investigate if eIF6 acutely
controlled ATP levels, we either silenced eIF6 by lentiviral-
mediated shRNA in wt hepatocytes or re-expressed eIF6 by
lentiviral-mediated infection in het hepatocytes. Brieﬂy, we found
that, in wt hepatocytes, eIF6 acute depletion reduced intracellular
ATP (Fig. 2f), whereas eIF6 overexpression, in het ones, increased
it (Fig. 2g). We asked whether eIF6 might steer the metabolic
activity of established cell lines. AML12 cells are derived from
non-tumourigenic murine liver hepatocytes. In AML12 cells, we
found that depletion of eIF6 by shRNA reduced glycolysis,
measured as lactate secretion (Fig. 2h), and ATP content (Fig. 2i).
The mTORc1 pathway is involved in the response to nutrients
and growth factors. We tested whether eIF6 acts upstream of
mTORc1 activation. Modulation of eIF6 levels did not affect
phosphorylation of rpS6 at Ser235, a substrate of mTORc1-S6K
cascade, and 4E-BP1, a substrate of mTORc1 (Supplementary
Fig. 2e). Taken together data demonstrate that eIF6 translational
activity steers the metabolism of cells in a cell autonomous fashion.
Speciﬁcally, eIF6 induces glycolysis and fatty acid synthesis.
Insulin-eIF6 modulate translation of lipogenic factors. Data
from Figs 1 and 2 suggest that eIF6 drives the translation of
speciﬁc factors that regulate a lipogenic switch. We analysed
how eIF6 modulates insulin-stimulated translation by using a
fast doxycycline-inducible system, combined with polysomal
microarray. Forty-eight hours after doxycycline treatment,
AML12 cells with inducible eIF6 shRNA presented a reduction of
eIF6 (Supplementary Fig. 3a) and resistance to insulin-stimulated
methionine incorporation (Supplementary Fig. 3b). Polysomal
analysis of insulin-stimulated cells showed that eIF6
downregulation reduced the polysome/80S ratio as expected by
the loss of eIF6 anti-association activity (Fig. 3a). In unstimulated
conditions eIF6 deﬁciency did not affect polysome peaks
(Supplementary Fig. 3c).
Next, we analysed mRNA from either polysomes or subpoly-
somes of insulin-stimulated cells by microarray analysis, (n¼ 4;
Fig. 3b; Supplementary Data 1). The analysis showed that eIF6
depletion induced a decrease in the polysomal occupancy of more
than 1,000 mRNAs (Fig. 3b). Moreover, after correcting for
polysome occupation, that is, absolute number of polysome
associated mRNAs, we found that up to 1/3 of genes expressed in
AML12 cells were inhibited by eIF6 depletion (5312/15405;
Fig. 3b). We conclude that a large subset of mRNAs, E1,000, is
strongly inhibited, under conditions of insulin stimulation and
depletion of eIF6. These mRNAs were further analysed.
Gene ontology analysis of strongly inhibited mRNAs showed
that they participated to metabolic processes and translation
(Fig. 3c). Notably, sterol regulatory element binding protein 1
(SREBP1), a transcription factor controlling glucose metabolism
and fatty acid production, modulated by mTOR (ref. 30), was not
found regulated at the polysomal level by eIF6 (Supplementary
Data 1). Sequence analysis demonstrated that the most affected
mRNAs inhibited by eIF6 depletion contained G/C rich regions
in their 50 UTR (Fig. 3d). Several transcription factors involved in
lipid synthesis were in the group of G/C rich mRNAs down-
regulated at the polysomal level by eIF6 depletion (Fig. 3e). By
contrast, mRNAs with less G/C content competed more
favourably onto polysomes (Fig. 3d), in the absence of eIF6.
Next, we tested the relevance of polysomal predictions by
quantifying, for some adipogenic transcription factors, the
eIF6-based regulation at the protein level. C/EBPd (ref. 31) is
an adipogenic transcription factor32. We found that eIF6
positively regulates C/EBPd protein, as predicted by polysomal
abundance, that is, eIF6 depletion reduces C/EBPd protein and
eIF6 upregulation increases it (Fig. 3f). In the same conditions,
C/EBPd mRNA was downregulated on polysomes by eIF6
depletion (Supplementary Fig. 3d). Sequence analysis of
lipogenic transcription factors downregulated on polysomes by
eIF6 depletion showed also the presence of uORF-containing
mRNAs. uORF repress translation, acting as insulators of the
downstream ORF, unless released by either reinitiation or leaky
scanning. Classically, uORF have been associated to sensing
stress, including amino-acid deﬁciency33,34. Our experiments
suggest that transcription factors containing uORF may be (also)
involved in lipid biosynthesis. We tested two transcription factors
containing established uORF sequences, C/EBPb and ATF4.
C/EBPb regulates adipogenesis35. C/EBPb mRNA generates,
through alternative translation three isoforms, LAP* (C/EBPb),
LAP and LIP (ref. 36). eIF6 shRNA downregulated C/EBPb
mRNA polysomal occupancy (Supplementary Fig. 3e). In the
same condition, we observed that LIP translation product of
C/EBPb was consistently downregulated, whereas LAP was not
(Figs 3g and 5e). ATF4 is a classical transcription factor with
uORFs regulated at the translation level by reinitiation. ATF4 is
robustly linked to the UPR37. However, the in vivo phenotype of
ATF4 depletion resembles eIF6 knockout phenotype with lower
cholesterolemia and resistance to fat accumulation38. Then, we
used an ATF4 uORFs-containing mRNA upstream of a luciferase
reporter, to speciﬁcally measure its translational efﬁciency in
conditions of eIF6 modulation. We found that eIF6 depletion
reduces ATF4 reporter activity and eIF6 overexpression increases
it (Fig. 3h).
In conclusion, we demonstrate that reduced eIF6 blunts
insulin-regulated translation of speciﬁc mRNAs regulating
metabolism. Speciﬁcally, we ﬁnd a robust change in the
translational activation of multiple transcription factors involved
in lipogenesis, which ﬁts the data presented in Figs 1 and 2, and
predicts further gene-expression modulation.
eIF6 axis elicits a translation to transcription programme. The
liver is a major insulin-responsive organ that responds to high
nutrients and high insulin by the induction of protein synthesis.
Driven by the observations that eIF6 regulates de novo lipogenesis
and the translation of (some) lipogenic transcription factors,
we aimed at deﬁning the genes affected downstream. We simul-
taneously assessed steady-state mRNA levels and polysome
associated mRNAs in liver of wt and het mice under feeding
conditions (Supplementary Data 2). We describe for clarity only
mRNAs whose levels change at the steady state (total).The gene-
expression signature of eIF6 depletion, at the steady-state mRNA
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level, was consistent with the metabolic and rapid translational
changes mastered by eIF6 activity, and extended them. Brieﬂy,
eIF6 depletion induced a peculiar gene-expression signature
marked by the downregulation of mRNAs encoding for key
proteins regulating cell cycle, DNA packaging, cholesterol and
lipid biosynthesis and glycolysis (Fig. 4a,b; Supplementary
Fig. 4a). The lipid biosynthetic programme was affected in liver
and fat, but not in brain (Fig. 4b).
Gene ontology analysis demonstrated that all enzymes involved
in fatty acid, sterol synthesis and glycolysis were signiﬁcantly
decreased more than twofold by eIF6 depletion (Fig. 4c). Among
them, we found ATP cytrate lyase, acetyl-CoA carboxylase 1 and
the rate-limiting enzymes fatty acid synthase (Fasn) involved in
lipogenesis, elongation of long-chain fatty acids family member 6
and stearoyl-CoA desaturase 1 catalysing fatty acids elongation
and desaturation step; Hmg-Coenzyme A synthase and Hmg-
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Figure 2 | eIF6 activity cell autonomously controls fatty acid synthesis, glycolysis and ATP levels. (a) Outline of the analysis. Primary hepatocytes from
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panels, data are represented as mean±s.d. Statistical P values were calculated by two-tailed t-test (*P value r0.05, ***Pr0.001). (e–i), N¼ 3.
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Coenzyme A reductase (Hmgcr) involved in cholesterol bio
synthesis. Srebp2, a cholesterol regulatory transcription factor was
downregulated in het liver (Supplementary Fig. 4). Two major
insulin-regulated transcription factors were found upregulated
upon eIF6 depletion: Foxo1, suggesting a strong link between
insulin signalling and eIF6-driven metabolic control and Pgc1-a
(ref. 39), which is a key transcription factor involved in
mitochondrial biogenesis and downregulated during lipogenesis
(Supplementary Fig. 4c. Messenger RNAs differentially affected at
the steady-state level by chronic eIF6 depletion, in vivo, were
validated on multiple samples and ages (Fig. 4d; Supplementary
Fig. 4b,c). For Fasn, Hmgcr, Pgc1-a and Foxo1 these changes
were also conﬁrmed at the protein level (Fig. 4e).
Next, we asked whether eIF6-induced changes were limited to
the liver or also present in other insulin-responsive organs. White
adipose tissue is controlled by systemic insulin. In contrast, the
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brain is unresponsive to systemic insulin due to the blood–brain
barrier. eIF6 depletion induced co-ordinated changes in gene
expression in fat and liver, but not in the brain (Fig. 4b;
Supplementary Data 3). Intriguingly, eIF6 het fat and liver shared
the downregulation of pathways regulating lipid and cholesterol
synthesis (Fig. 4b,c). Muscle is also a major insulin responder.
Analysis of liver, fat, muscle and brain at different ages showed
that chronic eIF6 depletion caused a co-ordinated downregula-
tion of Fasn mRNA and an increase in Pgc1-a mRNA39 in all
insulin-responsive tissues, but not in brain (Supplementary
Fig. 4c). Consistent trends were in general observed for muscle,
fat and liver, but not brain for all genes studied with the notable
exceptions of Zbtb16 that is liver speciﬁc and Foxo1, which was
not changed in muscle (Supplementary Fig. 4c).
In conclusion, we show that impairment of translation, due to
eIF6 depletion, causes a stable and co-ordinated change of gene
expression of metabolic key-players at the mRNA level in insulin-
responsive tissues, which leads to reduced lipogenesis. Thus, eIF6
is a translational regulator of metabolism, acting upstream of
transcription.
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Fasn is a marker of eIF6 activation. Fasn is a rate-limiting
enzyme of fatty acid synthesis40, primarily induced by insulin. We
demonstrated that its levels are downregulated by chronic eIF6
depletion in liver (Fig. 4) and that eIF6 induces the translation of
lipogenic transcription factors. We therefore asked whether eIF6
could rapidly induce Fasn mRNA expression. We addressed the
question in two models, liver-derived AML12 hepatocytes and
mesenchymal stem cells (EMSC) differentiated to adipocytes. We
either reconstituted or depleted eIF6 in these models (Fig. 5a). We
found that depletion of eIF6 by using an inducible shRNA for
eIF6 in AML12 hepatocytes led to a reduction of Fasn mRNA
levels (Fig. 5b). eIF6 depletion led to a reduction of Fasn mRNA
also in wt EMSC differentiated to adipocytes (Fig. 5c). Het EMSC
differentiated to adipocytes express less eIF6 than wt cells. Next,
we re-expressed eIF6 in het EMSC differentiated to adipocytes.
Re-expression of eIF6 in het EMSC adipocytes restored Fasn
mRNA levels (Fig. 5d).
Three alternative mechanisms may account for Fasn mRNA
increase/decrease on eIF6 overexpression or depletion. First,
variations in Fasn mRNA stability; second, effects of eIF6
expression on signalling pathways regulating transcription of
Fasn mRNA, such as the mTOR pathway; third, translational
regulation of transcription factors that shape fatty acid synthesis.
To assess Fasn mRNA stability, we performed a time-course
experiment after Actinomycin-D treatment in hepatocytes
depleted for eIF6 and matched controls. We established that
eIF6 depletion does not decrease Fasn mRNA stability
(Supplementary Fig. 5a). mTOR controls both translation and
lipogenic pathways. To rule out the possibility that eIF6 depletion
impaired either the mTOR or the Akt pathway, we checked the
phosphorylation state of both mTORc1 and mTORc2 substrates
(although eIF6 is not downstream of mTOR activation).
We found that eIF6 depletion, although generating a blunted
insulin-translational response, does not induce changes in the
phosphorylation of lipogenic pathways such as mTORc1,
mTORc2 and ERK (Supplementary Fig. 5b). Also phosphoryla-
tion of IRS1, Akt, ERK, S6 and 4E-BP1 was not altered in the liver
of het mice where eIF6 depletion is prolonged, consistent with
insulin signalling unchanged by eIF6 (Supplementary Fig. 5b).
Finally, consistent with the hypothesis that eIF6 regulates Fasn
transcription through the translation of transcription factors,
depletion or overexpression of eIF6 simultaneously modulated
both Fasn protein and C/EBPb LIP isoform (Fig. 5e). Thus, Fasn
expression can be used, in our system, as a model mRNA to test
the efﬁcacy of eIF6 inhibition.
eIF6 targeting results in Fasn modulation. Insulin-resistant
conditions, such as obesity and type 2 diabetes, and cancer may
arise from a common Fasn-dependent lipogenic state40. To
discover possible functional connections between drugs action
and eIF6 genetic perturbations, we analysed our microarray data
through the Connectivity Map tool41, an online resource that
enables the discovery of functional connections between drugs
and genes through the feature of common gene-expression
changes (Fig. 6a). We found that eIF6 depletion ‘signature’ was
similar to the one obtained by two translation inhibitors (Fig. 6b),
ciclopirox (inhibiting eIF5A) and puromycin, binding the
peptidyl transferase center (PTC) pocket in the large 60S
subunit. eIF5A has been recently proposed to stimulate peptide-
bond formation between proline residues42. Puromycin is an
elongation inhibitor and one of the most potent inducer of
termination of translation and peptide release. Other translational
inhibitors like cycloheximide did not score signiﬁcantly in this
experiment. Two other top scorers were surprising, the histone
deacetylase (HDAC) inhibitors, trichostatin A and MS-275
(Fig. 6b). HDAC inhibition has been recently suggested as
effective in the treatment of type 2 diabetes43. We tested the
hypothesis that HDAC inhibitors were able to modulate Fasn
expression or eIF6 activity (Fig. 6c), as expected by the
connectivity map. Indeed, 48 h treatment with TSA or MS-275
led to a reduction of Fasn mRNA (Fig. 6d). Short-term pulse with
TSA or MS-275 did not alter initiation of translation
(Supplementary Fig. 6). Since we found that chromatin
remodelling appeared also in the Gene Ontology analysis, (see
Fig. 4a), we tested the hypothesis that eIF6 regulates histone
acetylation. Consistently with the connectivity map, eIF6
downregulation leads to histone hyperacetylation both in liver
and in AML12 cells (Fig. 6e).
In several models, eIF6 activation requires phosphorylation of
eIF6 Ser235 (refs 17,22). Targeting eIF6 may be achieved using
drugs that reduce eIF6 activation (Fig. 6f) by the PKC
pathway17,22. Therefore, we expressed wt and mutant eIF6 in
EMSC cells differentiated to adipocytes and measured eIF6 levels
and Fasn expression. Figure 6g,h show that Fasn levels are not
increased by Ser235Ala mutant eIF6, but only by wt eIF6.
In conclusion, either blocking eIF6 expression by HDAC
inhibition or eIF6 activity by inhibition of its phosphorylation
results in Fasn modulation providing proof-of-concept that eIF6
can be targetable. We conclude that the translational branch
driven by insulin-eIF6 regulates long-term adaptation to high
nutrient levels by eliciting glycolysis and lipogenesis (Fig. 6i).
Discussion
We demonstrate that eIF6 translational activity regulates the
lipogenic programme through the co-ordinated upregulation of
enzymes involved in cholesterol and fatty acid synthesis. eIF6
acts in a cell autonomous fashion inducing the translation of
lipogenic transcription factors like C/EBPb, C/EBPd and ATF4
characterized by rich G/C sequences or uORF in their 50 UTR.
The rate-limiting effect of eIF6 is evident after insulin
stimulation. Thus, eIF6 activity links translation with metabolism
affecting insulin sensitivity. The stimulatory effect of insulin on
translation has been known for decades44; nonetheless, neither its
physiological signiﬁcance, nor its relevance for glycemic control is
understood. By exploiting the ﬁnding that insulin-stimulated
translation is blunted in eIF6-depleted cells, we demonstrate that
insulin-stimulated translation is functional to the induction of
transcriptional changes essential for the metabolic switch toward
glycolysis and lipogenesis.
The switch to glycolysis and fatty acid synthesis induced by
eIF6 in a cell autonomous fashion has implications in cancer.
Indeed, the Warburg effect is a metabolic switch observed in
cancer cells, where increased aerobic glycolysis is preferentially
used as source of energy over oxidative phosphorylation. In
addition, Fasn is a rate-limiting enzyme of de novo lipogenesis, a
pathway needed to build membranes during oncogenesis40.
Recently, we reported that eIF6 het mice were highly resistant
to Myc-induced lymphomagenesis with up to 40% survival at
1 year. Myc is itself an inducer of glycolysis and protein
synthesis45,46. Therefore, the anti-cancer role of eIF6 inhibition
may be linked to its metabolic effect, counteracting Myc action.
Transformed cells carrying the Ser235Ala eIF6 mutant, not toxic
in vitro, cannot grow as xenografts. It follows that the mere
hyperactivation of eIF6 and/or the translational machinery can
explain part of the Warburg effect. Indeed, eIF6 is highly
expressed in human aggressive tumours47, also by gene
ampliﬁcation21. Thus, our data further stress the powerful role
that translation has in tumourigenesis48.
eIF6 facilitates the translation of mRNAs with G/C rich or
uORFs sequences. We stress two facts. First, uORF-containing or
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G/C rich mRNAs are generally translated with poor efﬁciency.
Second, eIF6 inhibition decreases also the rate of protein
synthesis. It is the combination of qualitative and quantitative
effects that results in a highly speciﬁc and powerful regulation of
lipid biosynthesis, neither of them would be probably sufﬁcient. It
must be stressed that this conclusion is relevant, because insulin
and growth factors always increase the rate of protein synthesis.
The observation that uORFs inhibition is linked to reduction
of lipogenesis in eIF6-depleted cells is somewhat unexpected,
given the predominant model of their function in the UPR or
amino-acid deﬁciency, but consistent with previous work
showing that inhibition of eIF4G reduces loading of these
mRNAs on polysomes29. We simply suggest that uORF can act as
barriers for translation that can be overcome by translational
stimulation. As such, they have been evolutionarily selected in
mRNAs encoding for transcription factors that exploit high
nutrient levels to build an anabolic response. Indeed, ATF4 role
in triglycerides synthesis is clear49. To address the precise role of
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translation in the regulation of glucose and lipid metabolism,
experiments of knockdown and rescue of uORFs sequences of
these speciﬁc transcription factors in vivo are required. The
genetic validation of translational control of metabolism will
provide a new model for gene expression and metabolic control.
An unexpected observation is the maintenance of glucose
tolerance, glucose uptake and glycogen synthesis in the presence
of resistance to insulin-induced translation, observed in eIF6-
depleted cells. In contrast, we see decreased glycolysis, fatty acid
synthesis and ATP content. This fact underlines the speciﬁcity of
the transcriptional programme elicited by eIF6 through transla-
tion. We provide a simple evolutionary model to explain our data.
Glucose-stimulated insulin secretion signals to cells ‘richness’
of nutrients. Cells convert this information in stimulation of
glycolysis and fatty acid synthesis through the translational
apparatus. Future studies are needed to investigate if the changes
that we see in glucose and lipid metabolism could be related also
to changes in energy charge. Our data ﬁt a model in which eIF6-
driven translation is a targetable feed-forward loop that induces
insulin resistance and tumour growth. Therefore, we propose that
translation, downstream of insulin, acts as a switch for ‘metabolic
learning’, that is, cells learn that they have nutrients (model,
Fig. 6i)50.
The effect of eIF6 on translation is not a simple by-product of
reduced ribosomal availability. First, knockout of 60S biogenesis
factors, like Bop1, impairs ribosome production, but not Fasn
levels (D.B., unpublished observations); second, eIF6 knockdown
‘signature’ is similar only to puromycin but not to cicloheximide,
another elongation inhibitor. Remarkably, puromycin and eIF6
are used together, in vitro, to dissociate post-termination
ribosomes51. Our data would suggest that the anti-association
activity of eIF6 is required to avoid inactive 80S formation after
termination and allowing the rapid recycling of the free 40S on
the adjacent start codon, in vivo.
The capability of translation, and eIF6, to steer metabolism has
wide implications in diabetes. One surprising observation is that
eIF6 inhibition is not pro-diabetic. In contrast, prolonged
mTORc1-mediated inhibition of translation by rapamycin
promotes diabetes onset9,10. It is unclear whether this effect is
due to the pleiotropic effects of mTOR inhibition or whether this
is due to the different step of translation inhibited by rapamycin.
Rapamycin inhibits 4E-BPs phosphorylation, impairing the 48S
formation step of initation, as well as elongation through eEF2
(ref. 7). eEF2 is linked to adaptation to nutrient deprivation52.
Our model supports the speciﬁcity of eIF6-driven translation.
Our data bring further emphasis on some redundancy of
insulin signalling pathways in cells. Good evidence shows that the
fatty acid synthesis programme is activated by SREBP1 and highly
stimulated by mTORc1 activity. Inhibition of lipogenesis is also a
hallmark of mTORc1 inhibition30. We did not observe changes
of SREBP1 at the transcriptional level or on polysomes
(Supplementary Data 1-2). We found that the mTOR pathway
is not altered by eIF6, as established by analysing pSer473-Akt,
p235/236-S6 and 4E-BP1 phosphorylation status. Currently, there
is no evidence that eIF6 is below the mTOR cascade. The
hyperphosphorylated C terminus of eIF6 is not fully
characterized21; the only characterized residue, phosphorylated
by PKC, is Ser235 (ref. 20). PKC/RACK1 complex phosphorylates
eIF6 contributing to its activation and tumour growth53
and RACK1 knockout mice have impaired PKC-stimulated
translation54. In addition, PKCbII knockout have a lean
phenotype and display resistance to obesity upon HFD55.
However, in spite of not being under mTOR control, eIF6
regulates similar downstream processes, as demonstrated by our
work. Therefore, the presence of an mTOR insensitive pathway,
that through eIF6 controls lipogenesis, is consistent with the
presence of alternative pathways converging on the regulation of
metabolism. This is supported also by pharmacological evidence
that mTOR inhibition can be bypassed by RAS mutations in
cancer cells13.
In conclusion, we have demonstrated that translational control
driven by eIF6 is sufﬁcient to steer metabolic choices in an
mTOR-independent fashion. We provide a mechanistic link
between obesity and cancer through eIF6 activity.
Methods
Mouse colony. eIF6þ /þ and eIF6þ / mice were generated22 and backcrossed to
C57BL/6N background (FZ24). Metabolism experiments were performed also on
a mixed 129 background with identical results. Both males and females were used.
Experiments were performed with mice aged 1–3 months. The health status of
mice was monitored every month according to the Federation of European
Laboratory Animal Science Associations (FELASA) recommendations. Animals
were genotyped and randomly analysed. There are no inclusion/exclusion criteria.
Animal studies were performed on mice that were age-matched. Primary cells were
always derived from littermates of the speciﬁed genotypes. Most measurements
were performed automatically without knowing the genotype of the animals until
analysis of data.
All experiments involving mice were performed in accordance to Italian
national regulations and experimental protocols reviewed by the local Institutional
Animal Care and Use Committees of the San Raffaele Research Institute (IACUC
no. 477). After 2010, we complied to Directive 2010/63/EU based on three R
principle.
Sample size was calculated by power analysis, set at minimum 85%. The
variance is similar between the statistically compared groups. In all cases, and for
all measurements at least three independent experiments each with at least two
couples of matched experimental subjects were used. The primary phenotypic
screening was performed on n¼ 40 mice/genotype. Mice were fully randomized.
Mice were housed with a 12 h light cycle (0700–1900 hours) and fed a standard
rodent chow unless speciﬁed. A cohort of mice (n¼ 20) was subject to HFD (27%
safﬂower oil) regimen for 36 days. At the end, GTT and ITT were performed and
insulin levels were measured.
PCR analysis. Genotyping of the offspring mice was performed as follows. Brieﬂy,
PCR was performed by AmpliTaq Gold (Roche) according to the manufacturer’s
protocol. A shared primer number 3 (50-GTGAGTCTGGCTTCATGTG-30) was
designed downstream of the deleted region. This primer can pair with wt allele-
speciﬁc primer number 2 (50-CTATGTGGCCTTGGTCCAC-30) to amplify a
320 bp PCR product or with the targeted allele-speciﬁc primer number 1 (50-GCA
GCGCATCGCCTTCTATC-30) in the neo cassette to amplify a 650 bp fragment
from the mutant allele. PCR products were resolved on 1% agarose gel.
GTT–ITT and clinical chemistry. For GTTs, randomized male mice (n¼ 6) were
fasted for 16 h and then injected intraperitoneally with 2 g kg 1 body weight
glucose. Blood glucose values were determined by an automatic glucose monitor
(Glucotrend 2, Roche) and Accu-Chek active bands (Roche)56. The ITT was
performed on mice fasted for 4 h, human insulin was administered by IP injection
at 1U kg 1. Blood glucose levels were monitored as above immediately before
injection (T0), and at 30, 60 and 120min after injection. Blood was collected by
retro-orbital puncture, centrifuged at 5,000g for 10min and plasmas were used for
the measurement of fasting blood glucose, cholesterol, triglycerides, non-essential
fatty acids levels and markers of hepatic function by an Olympus AU400 chemistry
analyzer.
Cell cultures. We used 293T (ATCC CRL-3216) and AML12 (ATCC CRL-2254)
cells. Cells were tested monthly for mycoplasma, and grown in Dulbecco’s modiﬁed
Eagle’s medium/Ham’s F-12 (GIBCO) supplemented with 10% foetal bovine
serum, a mixture of insulin, transferrin and selenium (Invitrogen), 40 mgml 1
dexamethasone and penicillin/streptomycin/glutamine solution (AML12) or fully
supplemented as above but with Dulbecco’s Modiﬁed Eagle’s Medium (DMEM;
293T). After shRNA-carrying lentiviral vector infection(s), cells were selected in
5 mgml 1 puromycin and shRNA was induced with 1mgml 1 doxycycline. For
mRNA stability experiments, actinomycin-D 5 mgml 1was added for 4, 8 and 24 h
to AML12 cells. For drugs treatments, cells were treated with ciclopirox 15 mM,
trichostatin A 100 nM, MS-275 10 mM and puromycin 7 mM for 30min before
polysome proﬁle analysis or for 48 h for gene-expression analysis.
Lentiviral infection. 293T cells American Type Culture Collection (ATCC) were
infected with packaging plasmid VSV-G, PMDLg/pRRE, pREV and transfer vector
pCCL-PPT-hPGK57. Full-length wt or Ser235Ala mutant eIF6 and GFP were
cloned in transfer vector. Primary hepatocytes were infected with eIF6wt-pCCL,
eIF6S235A-pCCL and GFP-pCCL. Multiplicity of infection was determined to
achieve twofold eIF6 expression by at least triplicate infections. For shRNA
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experiments, 293T cells were infected with packaging plasmid ENV, pMDG,
pD8.74 and pGIPZ plasmids carrying scramble shRNA or two eIF6-speciﬁc
shRNAs, deﬁned after a screening of four sequences. For inducible shRNA of eIF6,
pINDUCER11 plasmids kindly provided by Thomas Westbrook were used58.
Mature antisense sequences were: 50-AGCTTCCTACTAGCACCTG-30 ; 50-AGA
AGTTCTCTGAGCCTCC-30 (Open Biosystem).
Dual luciferase assay. Plasmid transfections of AML12 cells at 50% conﬂuency
were performed by using calcium phosphate method. Cotransfections of 50%
conﬂuent AML12 were carried out in triplicate by using TK-ATF4-Luc fusion
plasmids (kindly provided by Ronald C. Wek) and a Renilla luciferase plasmid
serving as an internal control (Promega). After transfection (40 h), AML12 cells
were treated with thapsigargin at 100 nM for 6 h or with no endoplasmic reticulum
(ER) stress. Dual luciferase assays were carried out accordingly to Promega
instruction manual after protein quantitation. Mean values o three independent
experiments are expressed as the ratio of ﬁreﬂy versus renilla luciferase units
(relative light units).
Ear mesenchymal stem cell culture and adipogenesis. Mesenchymal stem cells
from outer ears of eIF6þ /þ and eIF6þ / mice were collected and differentiated
into the adipogenic lineage with DMEM-F12 supplemented with 4% foetal bovine
serum, 1.7 mM insulin, 1 mM dexamethasone and 0.5mM IBMX59 for 10 days.
Differentiated cells were ﬁxed in 10% buffered formalin and stained with Oil Red O
for 10min. The dye retained by the cells was eluted with isopropanol and
quantiﬁed by measuring absorbance at 500 nm.
Hepatocyte isolation. Three-months-old mice or young mice, up to 4 weeks, were
anaesthetized by intraperitoneal injection of avertin. Liver was perfused in situ
through the portal vein with two different perfusion media: T1 solution pH 7.4
(0.9% NaCl, 0.05% KCl, 0.2% HEPES and 0.08mgml 1 EGTA) and T2 solution
pH 7.4 (0.6% NaCl, 0.05% KCl, 1.2% HEPES, 0.07% CaCl2 and 3 gml 1
collagenase type I). Flow rate was 5mlmin 1. After collagenase digestion,
hepatocytes were ﬁltered through a 70 mm cell strainer and passed on a 37.5%
PERCOLL cushion (Amersham). Pellet of viable cells was resuspended in DMEM-
F12 and recovered at 5% CO2, 37 C for 16 h before starting the experimental
procedure60. Matched littermates were always analysed in parallel.
Protein synthesis measurement by 35S-methionine labelling. Primary
hepatocytes or AML12 hepatocytes were used for analysis of translational rate.
Cells were seeded at sub-conﬂuency in six-well plates, and insulin stimulation was
performed at 100 nM for 30min. Metabolic labelling was performed as described
previously22.
Glucose uptake. Glucose uptake was measured as the incorporation of
radiolabeled 2-deoxyglucose61, in hepatocytes and 3T3-L1 differentiated
adipocytes. Brieﬂy, 2 105 cells per well were grown in 12-well plates and serum-
starved for 16 h. The cells were then washed twice with Krebs-Ringers Henseleit
(KRH) buffer (20mM HEPES pH 7.4, 136mM NaCl, 4.7mM KCl, 1.25mM
MgSO4 and 1.25mM CaCl2) containing 0.1% bovine serum albumin (BSA) and
incubated for 15min in 0.45ml KRH/BSA, followed by addition of 0.1 mM cold
2-deoxy-D-glucose and 0.5 mCi 2-deoxy-D-[3H]-glucose (Perkin Elmer) for 4min.
Following the incubation, cells were placed on ice, washed twice with ice-cold PBS
and lysed in 0.5ml of 0.05% sodium dodecyl sulfate (SDS). The lysate (0.4ml) was
counted in 5ml of scintillation ﬂuid using a Beckman LS6500 scintillation counter.
Rates of non-speciﬁc glucose uptake were determined in samples pre-treated for
10min with cytochalasin B (10 mM, Sigma) and were subtracted from the total
uptake. The speciﬁc glucose uptake was normalized to protein content.
Measurements of lactate secretion. Hepatocytes were plated at 2 105 cells per
well in 12-well dishes in high-glucose medium for 24 h (ref. 62). Cells were
switched to serum-free high-glucose medium for 4 h. Lactate secreted into the
medium was measured using the ﬂuorescence mode of a Lactate Assay Kit
(Biovision). Average of ﬂuorescent intensity was calculated for each condition
replicates. Values were normalized to protein content obtained from the same
wells30.
De novo lipogenesis. Hepatocytes were plated at 2 105 cells per well in 12-well
dishes in serum-free, high-glucose medium for 20 h. Cells were switched to serum-
free, low-glucose (1 gr l 1) medium plus 4 mCiml 1 D-[6-14C]-glucose (Perkin
Elmer) for 4 h before lipid extraction. As a background control, one sample was
labelled for just 1min before extraction. Cells were washed twice with Dulbecco’s
phosphate-buffered saline (D-PBS) before lysing in 0.5% Triton X-100. The lipid
fraction was extracted by sequential addition of chloroform and methanol (2:1 v/v)
with vortexing. After washing with water, phase separation was achieved by low-
speed centrifugation (1,000 r.p.m., 15min). 14C incorporation into the lower lipid-
containing phase was counted in 3ml scintillation ﬂuid. Each condition was
assayed in triplicate. After subtracting background values, average readings were
normalized to protein content30.
Fatty acid oxidation. Liver were homogenized in sucrose-Tris-EDTA (STE) buffer
containing 0.25M sucrose, 10mM Tris and 1mM EDTA (or EGTA). The reaction
mixture (100mM sucrose, 10mM Tris-HCl, 5mM KH2PO4, 0.2mM EDTA, 0.3%
fatty acid-free BSA, 80mM KCl, 1mM MgCl2, 2mM L-carnitine, 0.1mM malate,
0.05mM coenzyme A, DTT, ATP and [14C]-palmitate) was dispensed in each
sample and incubated for 60min at 37 C. At the end of the incubation period, the
reaction mixture was transferred to vials containing perchloric acid and highly
basic ﬁlter paper in the cap and incubated for 1 h. Then, the ﬁlter paper disc,
indicating the amount of CO2 liberated by fatty acid oxidation, was transferred to a
glass scintillation vial with liquid scintillation counting cocktail. Average counts per
minute (c.p.m.) were measured over 3min (ref. 63).
ATP content. Liver (200mg) or AML12 cells were homogenized in 6% (v/v)
ice-cold HClO4. Extracts were centrifuged at 10,000g for 10min at 4 C. The acid
supernatant was neutralized with KCO3 and used for luminometric determination
of ATP (ATP determination kit, Molecular Probes) by the method of Lundin64.
Glycogen assay. Liver samples from 5 h-refed mice were homogenized in 6%
perchloric acid (500ml/100mg tissue). Precipitates were pelleted and the super-
natant was collected. One volume of H2O was added and the solution was adjusted
to pH 6.5 with 10N KOH. A fraction of each sample was then incubated with ﬁve
volumes of amyloglucosidase (1mgml 1 in 0.2M (pH 4.8) acetate buffer) at 40 C
for 2 h. Glucose concentrations were then determined using the Amplex Red
Glucose/Glucose Oxidase Assay Kit (Invitrogen). Samples incubated in the absence
of amyloglucosidase were used as baseline controls62.
Histological staining. Tissue samples were excised from eIF6þ /þ and eIF6þ /
mice and immediately ﬁxed in 10% formaldehyde in 0.1M phosphate buffer (PBS)
at pH 7.4. Serial 3 mm sections of parafﬁn-embedded liver were stained with
haematoxylin and eosin for morphological analysis or subjected to PAS staining.
Brieﬂy, sections were hydrated and oxidized in 0.5% periodic acid solution for
5min. Then, slides are placed in Schiff reagent for 15min. At the end of the
procedure, sections were washed in tap water and counterstained with haema-
toxylin for 1min. Stained samples were observed in a Zeiss Axiophot microscope
and pictures were acquired with Scion Image Software.
Polysomal proﬁles. Polysomal proﬁles were performed as follows. In brief,
AML12 were lysed in 30mM Tris-HCl, pH 7.5, 100mM NaCl, 30mMMgCl2, 0.1%
NP-40, 10mgml 1 cycloheximide and 30Uml 1 RNasin. The liver was gently
homogenized in 50mM Tris-HCl, pH 7.8, 240mM KCl, 10mM MgSO4, 5mM
DTT, 250mM sucrose, 2% Triton X-100, 90 mgml 1 cicloheximide and 30Um 1
RNasin using a glass douncer. Heparin (100 mgml 1) was added to the liver
extract. After centrifugation at 12,000 r.p.m. for 10min at 4 C, cytoplasmic
extracts with equal amounts of RNA was loaded on a 15–50% sucrose gradient and
centrifuged at 4 C in a SW41Ti Beckman rotor for 3 h 30min at 39,000 r.p.m.
Absorbance at 254 nm was recorded by BioLogic LP software (BioRad) and ten
fractions (1.5ml each) were collected for subsequent proteins and RNA extraction.
mRNA extraction and real-time RT–PCR. Total RNA from tissue and cells was
extracted with TRIzol reagent (Invitrogen). For total, subpolysomal and polysomal
RNA extractions from sucrose gradient aliquotes, the sucrose fractions were
divided in two. The pulled fractions 1–6 and 7–10 were used for subpolysomal and
polysomal RNA. Afterward, samples were incubated with proteinase K and SDS 1%
for 1 h at 37 C. RNA was extracted by phenol/chloroform/isoamyilic acid method.
After treatment of total RNA with RQ1 RNase-free DNase (Promega), reverse
transcription was performed with Moloney Murine Leukemia Virus (MMLV)
reverse-transcriptase enzyme (Promega) according to the manufacturer’s instruc-
tions. Reverse transcribed complementary DNA (100 ng) was ampliﬁed with the
appropriate primers. For liver microarray validation, Taqman probes speciﬁc for
eIF6 (Mm04208296_m1), Fasn (Mm00662319_m1), Srebp1 (Mm00550338_m1),
Srebp2 (Mm01306292_m1), Chrebp (Mm02342723_m1) Pgc1a
(Mm01208835_m1), Foxo1 (Mm00490672_m1), Cdkn1a (Mm00432448_m1),
Ccnb1 (Mm03053893_gH) and Zbtb16 (Mm01176868_m1) were used. Probes
speciﬁc for syb green: GcK (Fw 50-ctggatgacagagccaggatg-30 ; Rw 50-agttggttcctcc-
caggtct-30); Pklr (Fw 50-ctggatggggctgactgtat-30 ; Rw; 50-ggcgtagctcctcaaacaac-30);
Stearoyl-CoA desaturase 1 (Fw 50-CTGACCTGAAAGCCGAGAAG-30 ; Rw
50-GCGTTGAGCACCAGAGTGTA-30); Hmgcr (Fw 50-TGTTCACCGGCAACAA
CAAGA-30 Rw 50-CCGCGTTATCGTCAGGATGA-30); Lxra (Fw 50-GAAGGAGA
GAGCCTTGCGTA-30 Rw 50-ATTTGGTTGGGTCAACAAGG-30); Lxrb (Fw
50-GTTTCCAGGGCAACAGAGTC-30 Rw 50-CAGAGAACTTGTGGGGGAAG-30)
were used. Srebp1, Srebp2, Chrebp Target mRNA quantiﬁcation by quantitative
reverse-transcriptase PCR (RT–PCR) using DDCt-method using Taqman Uni-
versal PCR Master Mix (4304437; Life Technologies, Invitrogen), with 18S rRNA as
an internal standard, was performed on an ABIPRISM 7900HT Sequence
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Detection System (Applied Biosystems). For polysomal microarray validation, the
following probes were used: Cebpd (Fw 50-ATCGACTTCAGCGCCTACAT-30, Rv
50-GCTTTGTGGTTGCTGTTGAA-30); Cebpb (Fw 50-CAAGCTGAGCGACGA
GTACA-30 Rv 50-AGCTGCTCCACCTTCTTCTG-30). Target mRNA quantiﬁca-
tion by quantitative RT–PCR using DDCt-method using SYBR Green Master Mix
(4344463, Life Technologies, Invitrogen), with 18S rRNA as an internal standard,
was performed on an ABIPRISM 7900HT Sequence Detection System (Applied-
Biosystems). The data were expressed as the percentage of relative quantity of target
genes. Results are represented as meansþ s.d. of three independent experiments.
Microarray hybridization and bioinformatic analysis. Transcriptional proﬁling
of murine tissue was performed with the use of Mouse Genome 430 2.0 Array
(Affymetrix). Labelling reactions and hybridizations were carried out according
to standard Affymetrix protocols (Affymetrix Genechip Fluidics Workstation).
Raw microarray data were normalized using the Robust Multi-array Average
algorithm65. Differentially expressed genes were detected using Signiﬁcance
Analysis of Microarrays66, a permutation based approach that allows the selection
of a desired false discovery rate (FDR). Differentially expressed genes with an FDR
o10% were deemed signiﬁcant. Lists of differentially expressed genes have been
functionally annotated using the web-based application DAVID67. A P value or
EASE score (signiﬁcance of gene–term enrichment with a modiﬁed Fisher’s exact
test) were calculated for each Gene Ontology term. A Benjamini–Hochberg FDR
correction for multiple testing was applied and a threshold of FDR o10% was
chosen for selecting signiﬁcant enrichment of speciﬁc Gene Ontology terms or
Kyoto Encyclopedia of Genes and Genomes pathways.
For microarray analysis on AML12, polysomal and subpolysomal RNAs were
hybridized on the Agilent SurePrint G3 Mouse GE 8x60K Microarray G4852A
following the manufacturer’s protocol. The experiment was performed in biological
quadruplicate. Hybridized microarray slides were scanned with an Agilent DNA
Microarray Scanner G2505C at 3 mm resolution with the manufacturer’s software
(Agilent Scan Control 8.1.3). The scanned TIFF images were analysed numerically
and the background was corrected using the Agilent Feature Extraction Software
version 10.7.7.1 according to the Agilent standard protocol GE1_107_Sep09. The
output of Feature Extraction was analysed with the R software environment for
statistical computing (http://www.r-project.org/) and the Bioconductor library of
biostatistical packages (http://www.bioconductor.org/). Low signal Agilent features,
distinguished by a repeated ‘undetected’ ﬂag across the majority of the arrays in
every condition, were ﬁltered out from the analysis, leaving 18,905 features
corresponding to 14,108 MGI genes. Signal intensities across arrays were
normalized with the quantile method. Polysomal, subpolysomal and translational
efﬁciency of differentially expressed genes (DEGs) were identiﬁed using linear
models and moderated t-test as implemented in the Bioconductor Limma and
tRanslatome packages (using a threshold of 0.05 on the Benjamini–Hochberg
corrected P values). Translational efﬁciency was calculated as the ratio between
polysomal and subpolysomal signals.
In addition to the standard procedure, for data on AML12, we include a
differential analysis. Brieﬂy, we modelled a correction ﬁlter that took in account the
fact that polysomes of eIF6 shRNA and methionine incorporation were lower than
in control cells (methionine incorporation het/wt 0.75; polysome area het/wt 0.6).
We applied the correction to a selected number of targets, to predict their actual
abundance, and veriﬁed it by digital RT–PCR. Wet validation conﬁrmed that
(relatively) upregulated mRNAs had similar (absolute) levels. We then include a
calculation sheet with this interpretation.
UTR analysis: 50 UTR sequences were downloaded from the UCSC Genome
Browser (http://genome.ucsc.edu/), assembly GRCm38/mm10. For each MGI
gene, the longest transcript variant was selected as representative of the gene.
Distribution analysis was performed on the GC content of 50 UTR regions
of the lists of DEGs. All the distributions were compared with the background
distribution corresponding to the whole set of mouse genes, and signiﬁcant
shifts were identiﬁed with the Mann–Whitney test.
Connectivity map analysis. To detect transcriptional signatures overlapping with
that of eIF6 haploinsufﬁciency, differentially expressed transcript IDs in the liver
were converted to the Affymetrix U133A platform, ranked according to statistical
signiﬁcance and uploaded to the Connectivity Map (Broad Institute) tool41. The
upregulated and downregulated genes in liver were compared with over 7,000
transcriptional signatures produced by in vitro treatment of cell lines with small
bio-active molecules.
Computed tomography method to determine liver fat content. Liver fat content
was non-invasively determined by X-ray attenuation in computed tomography
(CT) images (La Theta; Aloka Ltd., Tokyo, Japan) of the liver of sedated mice
(continuous 2–2.5% isoﬂurane inhalation). A sagittal pre-scan was used to identify
ﬁxed anatomical landmarks to deﬁne a region from the proximal end of the
eleventh thoracic vertebra to the distal end of the third lumbar vertebra.
A polygonal region of interest in the ventral part of the liver was deﬁned in three
consecutive slices and analysed using the La Theta 2.10 software. Averages of
computed tomography values of these region of interests were used to determine
liver attenuation to estimate liver fat content.
HOMA-IR analysis. A previously published and independent data set was used to
conﬁrm a clinical link between the expression of eIF6 and insulin sensitivity
(GSE27949). This data set deﬁnes the basal transcriptional state of subcutaneous
adipose tissue from 33 healthy subjects with ranging glucose tolerances. Their
mean (s.d.) age, body mass index (BMI) and VO2max were 52.5 (11.7) years, 31.4
(7.3) kgm 2 and 45.5 (13.7)ml O2 per kg per minute. HOMA-IR was calculated
for each participant by multiplying fasting glucose with fasting insulin dividing by
22.5. HOMA-IR was log transformed to approximate normality for regression
analyses. Two CEL ﬁles were removed because they appeared to have technical
issues based on quality diagnostics using the affyPLM Bioconductor package:
GSM691122 and GSM691134. The affy package was then used to carry out RMA
based normalization68,69. All analyses were performed using Bioconductor in R69.
Western blotting and antibodies. SDS-PAGE were performed on protein extracts
obtained from liver or hepatocytes homogenized in radioimmunoprecipitation
assay buffer (RIPA) (10mM Tris-HCl, pH 7.4, 1% sodium deoxycholate, 1% Triton
X-100, 0.1% SDS, 150mM NaCl and 1mM EDTA, pH 8.0). The following anti-
bodies were used: rabbit polyclonal antibody against eIF6 (1:3,000) (ref. 70). From
Cell Signaling Technology antibodies were directed against: Fasn (1:1,000; #3180);
acetyl-Histone H3 (Lys9) (1:1,000; #8173); Histone 3, (1:1,000; #4620); Foxo1
(1:1,000; L29) (#9454); phospho(Ser636/639)-IRS1 (1:1,000 #2388);
phospho(Ser473)-AKT (1:1,000; #4060); AKT (1:1,000; #9272); phospho(Ser235/
236)-S6 (1:1,000; #4858); S6 (1:1,000; #2217); 4E-BP1 (1:1,000; #9644);
phospho(Thr202/Tyr204)-ERK (1:1,000; #4370); ERK (1:1,000; #9102); and
phospho-(Thr638/641)-PKC beta (1:1,000; #9375). From other suppliers: PKC beta
(1:1,000; C-18) sc-210 Santa Cruz Biotechnology; Cebpd (1:500; M-17) sc-636
Santa Cruz Biotechnology; Pgc1a (1:500; H300) sc-13067 Santa Cruz
Biotechnology; lamin B (1:1,000; M-20) sc-6217 Santa Cruz Biotechnology; Hmgcr
(1:500; ABS229) Merck Millipore; C/EBPb (1:500; 1H7) 626002 Biolegend; b-actin
(1:10.000; AC-15) A5441 Sigma; Lamin B (1:1,000; M-20) sc-6217 Santa Cruz
Biotechnology.
Quantitation was performed on samples by running parallel lanes with
replicates. Each lane was ﬁrst normalized to b-actin and then normalized to the
control sample. Relative expression ratios were obtained by densitometry using the
ImageJ software. Uncropped images of the western blots membranes were shown
in Supplementary Fig. 7.
Statistical analysis. For comparing pair-wise genotypes on a single parameter,
unless otherwise speciﬁed, results are given as the mean±s.d. Statistical P values
calculated by two-tailed t-test were indicated: one asterisk for P values o0.05, two
asterisks for P values o0.01, three asterisks for P values o0.001.
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